Shop Apotheke Europe N.V. re-confirmed earnings guidance for 2022. For the full-year 2022, the Management Board expects to grow everything-but-Rx (non-Rx) sales by double-digits in the range of 15 to 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110.1 EUR | +0.55% | -8.33% | -16.34% |
Apr. 26 | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
Apr. 26 | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.34% | 2.42B | |
-31.75% | 15.68B | |
-24.17% | 12.39B | |
-23.58% | 6.74B | |
-5.31% | 6.29B | |
+10.76% | 6.26B | |
+70.00% | 4.95B | |
-2.48% | 4.66B | |
-6.60% | 4.03B | |
-9.24% | 3.62B |
- Stock Market
- Equities
- RDC Stock
- News Redcare Pharmacy NV
- Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022